Aerocrine signs distribution deal with Intramedic for Sweden

Solna (Sweden) and Copenhagen (Denmark) – December 18, 2013 – Aerocrine AB (OMX
Nordic Exchange: AERO) today announces the signing of an exclusive agreement
with Danish medical device company Intramedic AB for distribution of Aerocrine’s
new airway inflammation monitor and test kit – NIOX VERO® – in Sweden.
The agreement goes into effect on January 1, 2014 and gives Intramedic exclusive
rights for the sales and distribution of Aerocrine’s new instrument NIOX VERO®
and test kits, used for diagnosing and monitoring patients with asthma. The
agreement also includes Intramedic taking on the support, sales and distribution
for the already installed base of Aerocrine’s NIOX MINO® devices in the Swedish
market.
“As we prepare to launch our new product NIOX VERO® in Sweden, we are very
pleased to partner with Intramedic, who is a leading sales and marketing
distributor with an existing and substantial Swedish operation who has proven
track record of success with NIOX products from the Danish market, a well
-fitting product portfolio and a customer-oriented corporate culture. This deal
is part of Aerocrine’s strategy of substantially growing the European business
in a cost-efficient manner,” says Linus Norrbom, International Sales Director at
Aerocrine AB.

Aerocrine is committed to maintaining a direct presence in the Swedish market to
support development of FeNO guidelines, KOL management and engagement with
payers. Aerocrine will continue to focus on developing opportunities in new
healthcare environments such as pharmacy and occupational health.
Aerocrine offers versatile and easy-to-use monitoring devices for fractional
exhaled Nitric Oxide (FeNO)-testing. Aerocrine’s compact hand-held devices for
research and clinical applications are used for routine measurements in both
specialist and primary care clinics, and can be used to improve the management
of allergic airway inflammation, such as asthma.

Intramedic has been the exclusive distributor of Aerocrine’s products in Denmark
for a number of years. The Danish partner successfully launched the NIOX MINO®,
the predecessor to NIOX VERO®, in Denmark and built an impressive base of
installed devices that generate significant sales of test kits.

“We are very proud to become Aerocrine’s exclusive distributor for Sweden and
look forward to working with both existing and new customers in this market
while also supporting Aerocrine’s efforts to further establish FeNO-testing as
standard of care method for measuring allergic airway inflammation in the
Swedish healthcare system,” says Jan Rando, CEO of Intramedic.
NIOX VERO® and NIOX MINO® offer added advantages for patient care, including
detecting allergic airway inflammation, determining the likelihood of
corticosteroid responsiveness, monitoring of airway inflammation to determine
the potential need for corticosteroid, and unmasking of otherwise unsuspected
non-adherence to corticosteroid therapy.

For more information, contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368
0336
Linus Norrbom, International Sales Director, Aerocrine AB, +46 8 629 07 90
Jan Rando, Chief Executive Officer, Intramedic AB, +46 171 468 380, +45
51 356 160

About Intramedic

Intramedic is a privately owned dynamic and expanding medical device company
with subsidiaries in Denmark and Sweden. Intramedic is marketing and maintaining
systems from a variety of the world’s leading manufacturers within
cardiopulmonary diagnostics, biomechanics and
rehabilitation.www.intramedic.dk (http://www.intramedic.dk/om-os/about-us/)

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as Asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® which
enables fast and reliable point-of-care measurement of airway inflammation. This
product plays a critical role in more effective diagnosis, treatment and follow
-up of patients affected with inflammatory airway diseases. Aerocrine is based
in Sweden with subsidiaries in the US, Germany, Switzerland and the UK.
Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007
(AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:00 am on December 18, 2013.

The agreement goes into effect on January 1, 2014 and gives Intramedic exclusive
rights for the sales and distribution of Aerocrine’s new instrument NIOX VERO®
and test kits, used for diagnosing and monitoring patients with asthma. The
agreement also includes Intramedic taking on the support, sales and distribution
for the already installed base of Aerocrine’s NIOX MINO® devices in the Swedish
market.
“As we prepare to launch our new product NIOX VERO® in Sweden, we are very
pleased to partner with Intramedic, who is a leading sales and marketing
distributor with an existing and substantial Swedish operation who has proven
track record of success with NIOX products from the Danish market, a well
-fitting product portfolio and a customer-oriented corporate culture. This deal
is part of Aerocrine’s strategy of substantially growing the European business
in a cost-efficient manner,” says Linus Norrbom, International Sales Director at
Aerocrine AB.

Aerocrine is committed to maintaining a direct presence in the Swedish market to
support development of guidelines, KOL management and engagement with payers.
Aerocrine will continue to focus on developing opportunities in new healthcare
environments such as pharmacy and occupational health.
Aerocrine offers versatile and easy-to-use monitoring devices for fractional
exhaled Nitric Oxide (FeNO)-testing. Aerocrine’s compact hand-held devices for
research and clinical applications are used for routine measurements in both
specialist and primary care clinics, and can be used to improve the management
of allergic airway inflammation, such as asthma.

Intramedic has been the exclusive distributor of Aerocrine’s products in Denmark
for a number of years. The Danish partner successfully launched the NIOX MINO®,
the predecessor to NIOX VERO®, in Denmark and built an impressive base of
installed devices that generate significant sales of test kits.

“We are very proud to become Aerocrine’s exclusive distributor for Sweden and
look forward to working with both existing and new customers in this market
while also supporting Aerocrine’s efforts to further establish FeNO-testing as
standard of care method for measuring allergic airway inflammation in the
Swedish healthcare system,” says Jan Rando, CEO of Intramedic.
NIOX VERO® and NIOX MINO® offer added advantages for patient care, including
detecting allergic airway inflammation, determining the likelihood of
corticosteroid responsiveness, monitoring of airway inflammation to determine
the potential need for corticosteroid, and unmasking of otherwise unsuspected
non-adherence to corticosteroid therapy.

For more information, contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368
0336
Linus Norrbom, International Sales Director, Aerocrine AB, +46 8 629 07 90
Jan Rando, Chief Executive Officer, Intramedic AB, +46 171 468 380, +45
51 356 160

About Intramedic

Intramedic is a privately owned dynamic and expanding medical device company
with subsidiaries in Denmark and Sweden. Intramedic is marketing and maintaining
systems from a variety of the world’s leading manufacturers within
cardiopulmonary diagnostics, biomechanics and
rehabilitation.www.intramedic.dk (http://www.intramedic.dk/om-os/about-us/)

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as Asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® which
enables fast and reliable point-of-care measurement of airway inflammation. This
product plays a critical role in more effective diagnosis, treatment and follow
-up of patients affected with inflammatory airway diseases. Aerocrine is based
in Sweden with subsidiaries in the US, Germany, Switzerland and the UK.
Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007
(AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:00 am on December 18, 2013.